Cargando…

The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small cell lung cancer patients treated with EGFR TKI

PURPOSE: To identify and clarify the roles of inflammatory markers in prognosis for advanced non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitor (TKI). PATIENTS AND METHODS: One hundred and twelve adenocarcinoma, clinical stage IV, NSCLC patients with either EGFR...

Descripción completa

Detalles Bibliográficos
Autores principales: Phan, Thang Thanh, Ho, Toan Trong, Nguyen, Hue Thi, Nguyen, Hang Thuy, Tran, Thu Bich, Nguyen, Son Truong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250106/
https://www.ncbi.nlm.nih.gov/pubmed/30510441
http://dx.doi.org/10.2147/IJGM.S174605
_version_ 1783372890410844160
author Phan, Thang Thanh
Ho, Toan Trong
Nguyen, Hue Thi
Nguyen, Hang Thuy
Tran, Thu Bich
Nguyen, Son Truong
author_facet Phan, Thang Thanh
Ho, Toan Trong
Nguyen, Hue Thi
Nguyen, Hang Thuy
Tran, Thu Bich
Nguyen, Son Truong
author_sort Phan, Thang Thanh
collection PubMed
description PURPOSE: To identify and clarify the roles of inflammatory markers in prognosis for advanced non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitor (TKI). PATIENTS AND METHODS: One hundred and twelve adenocarcinoma, clinical stage IV, NSCLC patients with either EGFR exon 19 deletion (E19del) or EGFR exon 21 L858R substitution mutation (L858R) were selected for this study. The blood cell count at different stages of treatment was used to calculate the inflammatory markers. The Kaplan–Meier statistics and Cox regression model were used to test the differences of progression-free survival (PFS) between groups by the optimal cutoff point of biomarkers. RESULTS: The median values of white blood cell (WBC), neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR) and platelet to lymphocyte ratio (PLR) in NSCLC patients tended to be reduced after 3 months treated with EGFR TKI and increased conversely when the disease develops progression (P<0.001). With an optimal cutoff point of 2.96, NLR is the best prognostic marker in prediction of clinical response among the investigated markers (area under the curve [AUC]=0.873, 95% CI: 0.821–0.926, P<0.001), and it is an independent predictive marker (OR=3.52, 95% CI: 1.42–8.71, P<0.001). With optimal cutoff point of 0.38, MLR is also a predictive marker in response evaluation (AUC=0.762, 95% CI: 0.691–0.832). Univariate analyses have shown that the larger tumor size (>3cm) and the high level of pretreatment NLR were associated with the shortening of PFS (HR=2.24, 95% CI: 1.04–4.83, P=0.039 and HR=2.67, 95% CI: 1.41–5.03, P=0.006, respectively). Multivariate analysis has shown that the elevated NLR is an independent prognostic marker for worse PFS of NSCLC patients treated with EGFR TKI (HR=2.15, 95% CI: 1.15–3.99, P=0.016). CONCLUSION: NLR and MLR are valuable markers in response evaluation for NSCLC patients treated with EGFR TKI. The elevated NLR is also an independent prognostic factor for worse survival.
format Online
Article
Text
id pubmed-6250106
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62501062018-12-03 The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small cell lung cancer patients treated with EGFR TKI Phan, Thang Thanh Ho, Toan Trong Nguyen, Hue Thi Nguyen, Hang Thuy Tran, Thu Bich Nguyen, Son Truong Int J Gen Med Original Research PURPOSE: To identify and clarify the roles of inflammatory markers in prognosis for advanced non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitor (TKI). PATIENTS AND METHODS: One hundred and twelve adenocarcinoma, clinical stage IV, NSCLC patients with either EGFR exon 19 deletion (E19del) or EGFR exon 21 L858R substitution mutation (L858R) were selected for this study. The blood cell count at different stages of treatment was used to calculate the inflammatory markers. The Kaplan–Meier statistics and Cox regression model were used to test the differences of progression-free survival (PFS) between groups by the optimal cutoff point of biomarkers. RESULTS: The median values of white blood cell (WBC), neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR) and platelet to lymphocyte ratio (PLR) in NSCLC patients tended to be reduced after 3 months treated with EGFR TKI and increased conversely when the disease develops progression (P<0.001). With an optimal cutoff point of 2.96, NLR is the best prognostic marker in prediction of clinical response among the investigated markers (area under the curve [AUC]=0.873, 95% CI: 0.821–0.926, P<0.001), and it is an independent predictive marker (OR=3.52, 95% CI: 1.42–8.71, P<0.001). With optimal cutoff point of 0.38, MLR is also a predictive marker in response evaluation (AUC=0.762, 95% CI: 0.691–0.832). Univariate analyses have shown that the larger tumor size (>3cm) and the high level of pretreatment NLR were associated with the shortening of PFS (HR=2.24, 95% CI: 1.04–4.83, P=0.039 and HR=2.67, 95% CI: 1.41–5.03, P=0.006, respectively). Multivariate analysis has shown that the elevated NLR is an independent prognostic marker for worse PFS of NSCLC patients treated with EGFR TKI (HR=2.15, 95% CI: 1.15–3.99, P=0.016). CONCLUSION: NLR and MLR are valuable markers in response evaluation for NSCLC patients treated with EGFR TKI. The elevated NLR is also an independent prognostic factor for worse survival. Dove Medical Press 2018-11-19 /pmc/articles/PMC6250106/ /pubmed/30510441 http://dx.doi.org/10.2147/IJGM.S174605 Text en © 2018 Phan et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Phan, Thang Thanh
Ho, Toan Trong
Nguyen, Hue Thi
Nguyen, Hang Thuy
Tran, Thu Bich
Nguyen, Son Truong
The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small cell lung cancer patients treated with EGFR TKI
title The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small cell lung cancer patients treated with EGFR TKI
title_full The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small cell lung cancer patients treated with EGFR TKI
title_fullStr The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small cell lung cancer patients treated with EGFR TKI
title_full_unstemmed The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small cell lung cancer patients treated with EGFR TKI
title_short The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small cell lung cancer patients treated with EGFR TKI
title_sort prognostic impact of neutrophil to lymphocyte ratio in advanced non-small cell lung cancer patients treated with egfr tki
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250106/
https://www.ncbi.nlm.nih.gov/pubmed/30510441
http://dx.doi.org/10.2147/IJGM.S174605
work_keys_str_mv AT phanthangthanh theprognosticimpactofneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithegfrtki
AT hotoantrong theprognosticimpactofneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithegfrtki
AT nguyenhuethi theprognosticimpactofneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithegfrtki
AT nguyenhangthuy theprognosticimpactofneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithegfrtki
AT tranthubich theprognosticimpactofneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithegfrtki
AT nguyensontruong theprognosticimpactofneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithegfrtki
AT phanthangthanh prognosticimpactofneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithegfrtki
AT hotoantrong prognosticimpactofneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithegfrtki
AT nguyenhuethi prognosticimpactofneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithegfrtki
AT nguyenhangthuy prognosticimpactofneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithegfrtki
AT tranthubich prognosticimpactofneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithegfrtki
AT nguyensontruong prognosticimpactofneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithegfrtki